Drug intelligence / Profile preview

NA-731

Development stage: Unknown
Lead developer: Biomed
Modality: Small Molecules

Overview

NA-731 is a small molecule drug candidate being developed by Biomed Industries, in collaboration with NeuroActiva, for the treatment of traumatic brain injury (TBI). The drug is designed to cross the blood-brain barrier and utilizes a proprietary technology platform focused on neurogenesis and neuroprotection. By stimulating the production of new neurons and protecting existing ones from further damage, NA-731 aims to improve recovery outcomes for patients suffering from brain trauma. It is currently in Phase 2A clinical development.

Beyond the preview

Go deeper on NA-731.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NA-731.

Explore the full profile